Tag: #NovoNordisk
-
Novo Nordisk’s Wegovy Shows Liver-Health Benefits Beyond Weight Loss in MASH Patients
Novo Nordisk’s once-weekly semaglutide 2.4 mg (Wegovy) demonstrated remarkable liver-health improvements in metabolic dysfunction-associated steatohepatitis (MASH) patients—even those with minimal weight loss—signalling a potential paradigm shift in the obesity-related liver-disease market.
-
Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-
Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera
The intense bidding war between Pfizer and Novo Nordisk over Metsera underscores just how fiercely the global obesity-drug market is being contested.